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1. Introduction
Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. When on multiple medications and complex
regimens, cardiac patients are at increased risk and particularly vulnerable to drug interac‐
tions. A rational and informed approach to drug interactions, based on scientific knowledge,
can reduce the chance of adverse effects and improve patient outcomes.
Cardiovascular drugs are used to treat various forms of illnesses, but there are often large
differences between individual patients in drug response and dosage requirement. Treat‐
ment that has been proven effective for one person can be ineffective or even dangerous for
another.
A drug produces its therapeutic effect when it reaches its target concentration in the blood‐
stream. Whether a steady therapeutic concentration is obtained largely depends on the bal‐
ance between the dose administered and the rate at which the body metabolises the drug.
An individual patient’s response to a drug is not totally predictable. Below the target thera‐
peutic range, a drug may be ineffective or, when it is higher, the drug may cause adverse
reactions or become toxic. To ensure the safe and effective action of many drugs, the concen‐
tration in the bloodstream and their clinical effects are monitored. If necessary, the dose can
be adjusted or the medication changed to achieve the best possible outcome.
To avoid unintended and untoward adverse drug reactions, the prescriber should use the
fundamental principles of pharmacology and pharmacogenetics. Several drugs are metabol‐
ised through the same pathways and knowledge of the potential pathway capacity could
help to predict treatment success. Variability in the reaction to medication may be due to
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age, gender, morbidity, co-medication, food components, smoking and environmental fac‐
tors. However, polymorphisms present in genes, are responsible for most of the variation.
Pharmacogenetic research and candidate gene approaches have succeeded in the identifica‐
tion of several genetic factors influencing treatment response. In particular, associations be‐
tween variants in CYP enzymes and transporter genes have been repeatedly associated with
different response and treatment--associated side effects [1-6]. Knowledge of pharmacoge‐
nomics is providing a key to understanding fundamentals of the drug interaction process.
A specific genotype might differ in its frequency in different ethnic populations, leading to
differences in drug response. However, gene combination between ethnic groups makes it
impossible for the practitioner to simply predict if a drug will be efficient or not. There is no
specific genetic definition of ethnicity and ethnicity does not sufficiently separate those for
whom a given therapy will be effective.
In contrast, the pharmacogenetics potentially presents a more effective way of identifying
responders, nonresponders and potential adverse drug reactions. Pharmacogenetics pro‐
vides defined clinical biomakers for individualised therapy [7].
Personalised medicine can be defined as a form of medicine that uses information about a
person's genes, proteins and environment to prevent, diagnose and treat diseases, including
predicting therapeutic response, nonresponse and likelihood of adverse reactions. Diagnos‐
tic biomarkers are necessary to successfully select patients for therapy, distinguish likely res‐
ponders from nonresponders, identify patients at high risk for adverse events, or select an
appropriate dose for safe and efficacious use of the therapy.
The human genome consists of approximately 3 billion base pairs (NCBI database) and the
sequence of these varies among individuals. These variations can change the function of
proteins that interact with a drug and hence, the response to a drug may differ among indi‐
viduals. Sequence variations in drug-disposition genes can alter the pharmacokinetics of a
drug and those in drug-target genes can change the pharmacodynamics of a drug.
When a genetic polymorphism alters the function of a protein that is involved in the absorp‐
tion, metabolism, distribution and excretion of a drug, the concentrations of the parent drug
or its active metabolites may be affected. For example, CYP2D6*4 polymorphism leads to
lower activity of a metabolising enzyme and the plasma concentrations of the parent drug
metabolised by cytochrome P-450 isoenzyme 2D6 may increase and concentration of metab‐
olites may decrease (some antidepressants). As a result, it could lead to the development of
toxicity. For prodrugs, when metabolites have pharmacologic activity, the genetic polymor‐
phism may reduce the drug response (some analgesics). Genetic polymorphisms that
change the activity of the drug target (pharmacodynamics) may also alter the drug response.
For example, vitamin K epoxide reductase complex subunit 1 gene polymorphisms influ‐
ence warfarin response and β1-adrenergic receptor gene polymorphisms after β-blocker re‐
sponse. Therefore, drugs can compete for binding sites on the receptors or be metabolised
by the same enzyme, consequently create dug-drug interaction problem.
The information about pharmacogenetic terms and recourses is presented in the Appendix.
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Early identification of patients who will be at a higher risk for the development of adverse
side effects and who will need dosage adjustment has the potential to help the clinician to
limit a patient’s exposure to drug side effects. Characterisation of drug metabolising poly‐
morphisms has been shown to be useful for identifying individuals who are poor drug me‐
tabolisers and at risk of developing adverse reactions, and several genotyping methods are
already being used in clinical settings (Table1). The evidence provided by pharmacogenetics
and pharmacogenomics can be successfully used for drug interaction interpretation.
Drugs Tests of polymorphisms Affected WSLHD Population*
Wafarin CYP2C9 1% - Poor Metabolisers, 15% - Intermediate
Phenytoin
Warfarin VKORC1 11% with altered function
Clopidogrel CYP2C19 4% - Poor Metabolisers, 13% - Intermediate, 20% -
Ultra fast metabolisers
Carvedilol CYP2D6 5% - Poor Metabolisers, 27% - Intermidiate, 1% - Ultra
fast metabolisers
Metoprolol
Propafenone
Propranolol
Quinidine
Isosorbide NAT1, NAT2 10-90%
Hydralazine
Warfarin Protein C Deficiencies 1/200 population, 2-5% Patients with Venous
Thromboembolism
Atorvastatin LDLR 1-5% Familial Cholesterolemia Patients
Statins SINM PhyzioType (50 genes) 10-30% Patients on statin (multi-gene biomarker
system manufacture results, no data available)
Table 1. Available Pharmacogenetics tests for cardiovascular medication. (*Western Sydney Population combined
data. WSLHD population is a mix of Caucasians, Asians and Africans.)
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2. Hypertensive drugs
Hypertension is a common condition associated with increased risk of stroke, heart failure,
ischemic heart disease, and chronic renal failure. Thiazide diuretics, β-blockers, ACE inhibi‐
tors, angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) are a com‐
mon first line treatment for hypertension [8].
Despite availability of many effective agents, only about 40 percent [9] of treated hyperten‐
sive patients have their blood pressure controlled, mostly due to the unpredictable individu‐
al responses to treatment. Blood pressure responses to monotherapy vary widely within
ethnic and gender subgroups [10].
Numerous studies have tried to establish associations between genetic polymorphisms and
response to antihypertensive drugs. New developments in pharmacogenetics and pharma‐
cogenomics already offer in pharmacogenetics and pharmacogenomics already offers the
opportunity to provide individualised drug therapy on the basis of a person's genetic make‐
up for some drugs, despite varied approaches in study designs and methodology. These
tests are provided by several laboratories and available at some hospitals; pharmacogenetic
methods will not only help to achieve treatment goals and limit adverse effects, but also
avoid drug interactions.
2.1. β-blockers
β-blockers through binding to β-adrenergic receptors (BAR) antagonise the binding of en‐
dogenous agonists. Variations in the gene encoding the β1-adrenergic receptor probably in‐
fluence the treatment outcome. Two single nucleotide polymorphism (SNPs), resulting in
Ser49Gly and Arg389Gly were identified and these variants demonstrate altered biological
function in vitro, including enhanced agonist induced adenylyl cyclase activation by Gly49
compared to Ser49 and by Arg389 compared to Gly389 [11].
Some studies have shown that the Arg389Arg genotype and Ser49/Arg389 haplotype are as‐
sociated with a greater response to blood pressure-lowering metoprolol [12].
The  differential  survival  of  Acute  Coronary  Syndrome  (ACS)  patients  treated  with  β-
blockers  was  associated  with  patients'  β-adrenergic  receptors  2  variant  Gly16Arg  and
Gln27Glu genotypes; however, β-adrenergic receptors 1 variants showed no significant as‐
sociations [13, 14].
No significant correlation has been found for outcomes of death, MI or stroke in coronary
artery disease patients on atenolol treatment and β-adrenergic receptors variants or haplo‐
types [15] and β-adrenergic receptors 2 variants in MI and stroke outcomes. However, the
case-control study found significant interaction with two SNPs in β-adrenergic receptors
variant and cardiovascular complications [16, 17].
Angiotensin-converting enzyme (ACE) genes variations were also associated with β-block‐
ers therapy outcome. In heart failure, patients survival without a transplant, has been as‐
sociated  with  the  angiotensin-converting  enzyme  I/D  genotype  (insertion/deletion).
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Patients with the D allele may derive greater benefits  from pharmacologic interventions
with Beta-blocker treatment,  probably through the decrease of  sympathetic  nervous sys‐
tem activity [18].
The effects of the CYP450 enzyme systems has been studied intensively during the last years
and its role in the metabolism of drugs and other endogenous and exogenous chemicals is
well defined. Numerous publications confirm the association of these enzymes with drug-
drug, drug-toxins and drug-food interactions. Polymorphisms in the gene coding for the
CYP2D6 isoenzyme, which catalyses the metabolism of β-blockers such as metoprolol, car‐
vedilol, timolol, and propranolol, may also affect blocker response. It has been demonstrat‐
ed that the clearance of the R(+) enantiomer of carvedilol was 66% lower and the area under
the concentration-versus-time curve 156% higher among poor metabolizers than extensive
metabolizers [19-22].
Some studies showed association with other genes. Genes involved in calcium signalling -
CACNA1C, CACNB2, and KCNMB1- were found to be associated with myocardial infarc‐
tion or stroke with β-blockers versus calcium channel blockers [23-25]. Variable stroke risk
by genotype was described for an MMP3 promoter polymorphism in patients treated with
lisinopril [26] and different treatment-related outcomes with thiazides and β-blockers, but
not diltiazem, by NEDD4L (protein reduce renal tubular expression of epithelial Na+ chan‐
nel) genotype [27].
Finally, the two studies by Schelleman et al reported no β-blocker interactions (for outcomes
MI or stroke) variants of angiotensin receptor II type 1 (AGTR1) and ACE [28, 29].
2.2. Diuretics
Diuretics may act at a number of sites, including the proximal tubule, the Loop of Henle,
and the distal and collecting tubules. Diuretics are thought to indirectly activate the renin-
angiotensin-aldosterone system and block sensitivity of blood vessels to catecholamines.
Thiazide diuretics are the drug of choice for initial therapy, but genes responsible for renal
sodium reabsorption can affect the patient's responsiveness to diuretic therapy.
Antihypertensive response in black African Americans is found to be associated with locus
at chromosome12q15 [30, 31] where the FRS2 gene is located, which is involved in fibroblast
growth factor signalling. FRS2 plays a role in vascular smooth muscle cell regulation.
Genome-wide association (GWA) studies are aimed at identifying common genetic variants
modulating disease susceptibility, physiological traits and variable drug responses. These
studies also provide further evidence for the large effects that single gene variants may exert
for some drugs. GWA has explained relatively large proportions of variability compared to
studies of traits such as disease susceptibility or physiological measurements. GWAS dem‐
onstrated that SNPs in lysozyme and Yeats domain-containing protein 4 (YEATS4 ) were as‐
sociated with response to diuretic [30].
Lynch et al. found that C carriers of the NPPA T2238C variant, which codes for the precur‐
sor of atrial natriuretic polypeptide, had more favourable clinical outcomes when treated
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with a diuretic, whereas individuals homozygous for the T allele responded better to a calci‐
um channel blocker [32].
Patients with SNP of T594M gene (epithelial sodium channel) variant responded more fa‐
vourably to amiloride therapy for BP control than to thiazide-based drugs. In cases of severe
hypokalemia, potassium-sparing diuretics such as amiloride or triamterene should be used
according to serum sodium and potassium levels [33, 34].
NEDD4L is also a candidate gene with a documented functional SNP, a role in sodium reab‐
sorption, and several studies have found an association between this SNP and blood pres‐
sure response with thiazides [27, 35].
A common functional polymorphism resulting in Gly460Trp in the α-adducin gene ADD1
has been associated with response to thiazides. This finding led to the development of a
novel antihypertensive drug class targeting adducin [36, 37]. Manunta et al. performed sin‐
gle SNP association analysis and combination analysis on ADD1 (Gly460Trp), NEDD4L,
WNK1 in a 4-week diuretic trial. They found ADD1 460Trp carriers had significantly greater
BP reduction than Gly460 homozygotes. When considered together, there was a significant
trend in decreases of systolic blood pressure (SBP) (ranging from −3.4 mm Hg to −23.2 mm
Hg) for different combinations of genotypes [35].The ADD1 Gly460Trp polymorphism has
been associated with an increased risk of myocardial infarction or stroke during thiazide di‐
uretic treatment [38] In contrast, these findings were not confirmed by other studies [39, 40].
The 825T allele in the G-protein is probably associated with a sodium-sensitive form of hy‐
pertension. Blood pressure declines for both the C/T and T/T genotypes were significantly
greater than for the C/C genotype. The study revealed that the decreases in blood pressure
varied on the basis of genotype and even after multiple regression analysis, genotype re‐
mained a significant predictor of blood pressure lowering [41].
2.3. Renin-angiotensin system inhibitors
Numerous genes from the renin-angiotensin system (RAS) pathway have been shown to
play a key role in the regulation of blood pressure and influence the cardiovascular sys‐
tem. Several  pharmacogenetic  studies of  the RAS were conducted.  However,  due to the
complexity  of  RAS,  associations  between  drug  efficiency  and  polymorphisms  are  not
consistent [42-45].
Angiotensin-converting enzyme (ACE) inhibitors prevent the conversion of angiotensin I to
angiotensin II in plasma and tissue and prevent the degradation of bradykinin. Clinically,
ACE inhibitors reduce peripheral vascular resistance and pulmonary capillary wedge pres‐
sure and increase cardiac output and renal blood flow. Treatment with ACE inhibitors in
hypertension has been associated with improvements in vascular compliance, regression of
left ventricular hypertrophy, improved systolic and diastolic function, and improvements in
insulin sensitivity [46]. One study showed that ACE DD polymorphism is associated with
poor collateral circulation (PCC). PCC in patients carrying the D allele may be associated
with endothelial dysfunction and elevated blood ACE levels in these patients [47].
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The insertion/deletion (I/D) in the angiotensin I-converting enzyme (ACE) gene is one of the
candidates for studies. The D allele has been associated with more improvement in coronary
endothelial dysfunction with ACE inhibitor therapy than the I allele [48]. Reductions in sys‐
tolic and diastolic blood pressures were significantly greater for patients with the D/D geno‐
type than for patients with the I/D and I/I genotypes [49].
Diastolic blood pressure tended to decrease more for the ACE I/I genotype than for other
ACE genotypes and the I/I genotype was also predictive of greater diastolic blood pressure
decline [50]. Decline in renal function during ACE inhibitor treatment tended to be greater
in heart failure patients with the ACE I/I genotype [51]. The I/I genotype has also been asso‐
ciated with increased susceptibility to the development of cough during ACE inhibitor ther‐
apy. After four weeks of therapy with an ACE inhibitor in healthy volunteers, the threshold
for cough was significantly reduced for the I/I genotype but not the D/D genotype [52].
Another gene of interest is the angiotensinogen (AGT) gene. It was reported that the angio‐
tensinogen 235Met/Thr polymorphism is also associated with RAS activity and drug re‐
sponses. In subjects on ACE inhibitor monotherapy with 235Thr allele the response is higher
than in the control group. Systolic and diastolic blood pressures were higher and the likeli‐
hood of using two or more antihypertensive medications was 2.1 times higher with the
235Thr polymorphism [53].
An association with polymorphisms in the angiotensin AT1 receptor (AGT1R) gene and
ACE inhibitors’ efficiency are found in some studies. The AGT1R mediates some negative
effects of angiotensin II, such as vasoconstriction, cardiac remodelling, and aldosterone se‐
cretion. Angiotensin II blockers bind to angiotensin II receptors, thereby antagonizing the ef‐
fect of angiotensin II, a potent vasoconstrictor [54]. The 1166C allele of AGT1R has been
associated with increased arterial responsiveness to angiotensin II in ischemic heart disease
and increased aortic stiffness in hypertension. During ACE inhibitor treatment, reductions
in aortic stiffness were reported to be three times greater in carriers of the 1166C allele than
in 1166A homozygotes [55, 56]. AGTR1 (C573T) and ACE (ID) association between ACE in‐
hibitor therapy and increased MI risk for carriers of the AGTR1 C573 allele were reported;
however, no significant interaction between ACE inhibitor treatment and ACE (ID) alleles
for either stroke or MI were found [28]. One research group found no associations between
BP response and ACE (ID), AGTR1 (A1166C), CYP11B2 (-344 C/T), AGT (-6 A/G) [57].
After 12 weeks of treatment with irbesartan (Angiotensin II Blocker), plasma concentration
of the drug was related to change in systolic BP in TT homozygotes of AGTR1 (C5245T) but
not for other genotypes [58].
3. Calcium Channel Blockers (CCBs)
Drugs in this class block voltage-gated calcium channels in the heart and vasculature, there‐
by reducing intracellular calcium. Calcium channel blockers drugs vary in their effect on
cardiac versus vascular calcium channels. CCBs fall into three subclasses: phenylalkyla‐
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mines, which are selective for the myocardium; dihydropyridines which mostly affecting
smooth muscle and benzothiazepines with a broad range.
A few studies describe some association; three SNPs in CACNA1C had significant associa‐
tions with treatment in a study of BP lowering with calcium channel blockers [59]; between
CYP3A5*3 and *6 variants and verapamil treatment for BP and hypertension risk outcomes
in blacks and Hispanics [60]; individuals that are homozygous for the T allele of NPPA
T2238C had more favourable clinical outcomes when treated with a calcium channel blocker
whereas C carriers responded better to a diuretic [32]. Beta Adrenergic Receptor 1 (BAR1)
Ser49-Arg389 haplotype carriers had higher death rates than those with other haplotypes
when treated with verapamil [15].
4. Anticoagulants
4.1. Warfarin
Warfarin is a widely used anticoagulant in the treatment and prevention of thrombosis. It
was initially marketed as a pesticide against rats and mice and is still used for this purpose.
It was approved for use as a medication in the early 1950s and is widely prescribed. Despite
its common use, warfarin therapy can be associated with significant bleeding complications.
Achieving a safe therapeutic response can be difficult because of warfarin’s narrow thera‐
peutic index and great individual variability in the dose required, which is mostly a conse‐
quence of individual genetic variants. This fact is well known among clinicians and the wide
range, from 1 mg/day to 20 mg/day, of warfarin maintenance doses are observed across the
population. To maintain a therapeutic level of anti-thrombosis and to minimise the risk of
bleeding complications, warfarin therapy requires intensive monitoring via the International
Normalized Ratio (INR) to guide its dosing. The INR is used to monitor the effectiveness of
warfarin and measures the pathway of blood coagulation. It is used to standardize the re‐
sults for a prothrombin time. INR is the ratio of a patient's prothrombin time to a control
sample, raised to the power of the index value for the analytical system used.
Several factors increase the risk of over-anticoagulation: genetic polymorphisms affecting
the metabolising enzymes, impaired liver function, drug interactions, congestive heart fail‐
ure, diarrhoea, fever, and diets rich in vitamin K [61] [62]. Nevertheless, genetic factors and
drug interactions mostly account for the risk of over-anticoagulation. Warfarin metabolism
involves primarily the cytochrome P450 (CYP) enzymes. Some loss-of-function CYP2C9 and
vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphisms are known to be
associated with decreased enzymatic activity and as a result, with an increased risk of hae‐
morhage. These are CYP2C9*2 (Cysl44/Ile359), CYP2C9*3 (Argl44/Leu359) and VKORC1
(-1639G>A) [63-65].
Warfarin-induced haemorrhage is an important complication of anticoagulation therapy. A
review of many studies shows average yearly rates of warfarin-related bleeding as high as
0.8%, 4.9%, and 15%, for fatal, major and minor bleeding complications respectively [66].
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Vitamin K is required by proteins C and S, together with clotting factors II, VII, IX, and X, to
allow assembly of the procoagulant enzyme complexes necessary to generate fibrin. Warfar‐
in as an anticoagulant agent has the ability to interfere with the recycling of vitamin K in the
liver. The pharmacologic effect of warfarin is mediated by the inhibition of vitamin K epox‐
ide reductase complex subunit 1 (EC 1.1.4.1) [67].
Warfarin consists of (R)- and (S)-warfarin enantiomers. (R)- and (S)-warfarins differ in their
relative plasma concentrations, in their antithrombotic potency and in the specific isoen‐
zymes responsible for their metabolism. (S)-warfarin has a 3 to 5 times greater anticoagulant
effect than the (R)-enantiomer and accounts for 60% to 70% of warfarin's overall anticoagu‐
lant activity. (S)-warfarin is metabolised almost exclusively by CYP2C9 [68-70].
The activity of the CYP2C9 enzyme has a significant impact on the clearance of (S)-warfarin
and as a consequence on anticoagulant effect. In the presence of genetic variations where the
activity of CYP2C9 is reduced, clearance of (S)-warfarin is also reduced. Activity of CYP2C9
between individuals can vary by more than 20-fold. (R)-warfarin is metabilised by multiple
different CYP enzymes [71].
While several single-nucleotide polymorphisms of CYP2C9 have been reported, the
CYP2C9*2 (Cysl44/Ile359) and CYP2C9*3 (Argl44/Leu359) polymorphisms have been identi‐
fied as clinically relevant [72]. Both of these variants are associated with decreased enzymat‐
ic activity [24, 73-78].
Homozygous CYP2C9*3 variant genotypes have only 5% to 10% metabolic efficiency com‐
pared to the wild-type genotype. As a result, compared to wild-type CYP2C9*1*1 controls,
enzyme activity and the median maintenance warfarin dose for CYP2C9*3*1 heterozygotes
was reduced by 40%, and by approximately 90% for CYP2C9*3*3 homozygotes [72-74].
Furuya [79] and Steward [75] showed that the CYP2C9*2 variant is also associated with re‐
duced warfarin elimination. Heterozygotes demonstrate 40% and homozygotes 15% of the
wild-type enzyme activity, causing dose adjustment for heterozygote CYP2C9*2 individuals
down to 20% less than the standard dose.
Margaglione [76] has also demonstrated bleeding rates as high as 27.9 per 100 patient-years
in carriers of CYP variants. In this study, findings were adjusted for other common variables
associated with increased bleeding risk, such as increased age, drug interactions and abnor‐
mal liver function.
Several studies of the *2 and *3 CYP2C9 polymorphisms consistently show that patients
with at least one CYP2C9 allele polymorphism have reduced warfarin requirements [76,
80-84]. Freeman [85] reported reduced warfarin weekly dosages for carriers of CYP2C9*2 or
CYP2C9*3 alleles compared with patients who were homozygous for the wild-type allele
(0.307 mg/kg/wk and 0.397 mg/kg/wk, respectively). Taube [83] compared warfarin mainte‐
nance dosages in 683 patients carrying different CYP2C9 genotypes. Mean warfarin mainte‐
nance dosages were 86% in patients with CYP2C9*1*2, 79% in patients with CYP2C9*1*3,
82% in compound heterozygotes CYP2C9*2/*3, and 61% in patients homozygous for
CYP2C9*2. Furthermore, Aithal [80] warns that even when warfarin dosages are decreased,
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carriers of CYP2C9 poor metaboliser alleles experience a rate of major bleeding that is 3.68-
fold higher than the rate seen in patients with the wild type genotype.
The frequency of CYP2C9 alleles is ethnically related [82, 86]. Approximately 20% of the
Caucasian population carries one of the loss-of-function CYP2C9 alleles, and it is estimated
that 1% of Caucasian carry two such alleles [71]. The frequency of the CYP2C9*2 allele re‐
portedly ranges from 8-13% in different Caucasian populations. CYP2C9*2 is present in 4%
of African-Americans and is rare among Japanese individuals [87, 88]. The frequency of
CYP2C9*3 is 6-10% among Caucasian populations and 3.8% in Japanese populations [88, 89].
This data suggests that a substantial fraction of the Caucasian patient population may carry
at least one defective CYP2C9 allele. In this group, the usual prescription dosage of warfarin
may lead to major or even life-threatening haemorrhage.
Warfarin is commonly prescribed in combination with selective serotonin reuptake inhibi‐
tors (SSRIs), as depression often coexists with cardiovascular disease. Case reports suggest
that some SSRIs can interact with warfarin to increase the likelihood of bleeding [90]. SSRIs
cause adverse effects in isolation [91, 92] and can interact with other medications by inhibit‐
ing various isoenzymes of the CYP450 enzyme group [93, 94]. It has been shown that metro‐
nidazole and cimetadine increase the prothrombin time in patients on warfarin therapy.
Chloramphenicol enhances warfarin's effect by inhibiting the action of the hepatic P450 sys‐
tem [71]. Some authors [95], [96] have warned that antidepressants with a known or predict‐
able interaction with warfarin, such as fluoxetine and fluvoxamine, should be avoided in
patients receiving warfarin because of the risk of adverse outcomes.
Drug-drug interaction is a main concern in adverse drug reactions. The primary complica‐
tion occurring with warfarin treatment is bleeding. SSRIs may increase the risk of bleeding
during warfarin therapy by hindering platelet aggregation through depletion of platelet se‐
rotonin levels [97-99]. Some SSRIs may also inhibit the oxidative metabolism of warfarin by
CYP 2C9 [95].
It has been shown that concurrent use of selective serotonin reuptake inhibitors and warfar‐
in increases the risk of hospitalisation due to haemorrhage [90, 98]. Drugs which affect sero‐
tonin may have a detrimental effect on platelet function, as drugs which inhibit the reuptake
of serotonin may decrease platelet serotonin levels leading to a reduction in serotonin-medi‐
ated platelet aggregation. Potential drug interactions can involve modification in either of
these mechanisms and may result in pharmacodynamic interference or enhancement of war‐
farin's action.
It  was  shown  that  major  and  moderate  drug-drug  interactions  with  warfarin  are  very
common  in  inpatients  and  are  associated  with  INR  results  outside  the  therapeutic
range.  The  most  common drugs  involved in  the  increase  of  anticoagulation effect  were
enoxaparin,  simvastatin,  omeprazole  and  tramadol.  Multivariate  analysis  showed  that
age,  length of  hospital  stay,  exposure  to  >/=4  major  or  moderate  drug interactions,  and
refusal  of  pharmacist  recommendations  contribute  significantly  to  the  patient's  INR  re‐
sult  >5 [100].
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One study demonstrated that acetaminophen, at 2 g/day or 3 g/day, enhanced the anticoa‐
gulant effect of warfarin in stable patients, thus requiring close INR monitoring in the clini‐
cal setting [101].
4.2. Heparin
One of the preventative treatments of thromboembolic disease in patients is a prescription
of heparin. However, heparin induced thrombocytopenia (HIT) is one of the most serious
adverse reactions. HIT consequences can include thromboembolic complications and death.
An association between the Fc receptor gene and the risk for HIT has been found in some
studies and it was demonstrated that the homozygous 131Arg/Arg genotype occurred sig‐
nificantly more often in patients with HIT than in the healthy volunteers’ group [102] [103] ;
however, another group have found no association [104]. Results are very preliminary and
more evidence are needed before it may be possible to genotype candidates for heparin ther‐
apy to identify those at risk for drug-induced thromboembolic complications.
5. Statins
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) have reduced coronary
and cerebrovascular events and overall mortality when used for both primary and secon‐
dary prevention of ischemic heart disease [105]. Several known gene polymorphisms are as‐
sociated with the treatment progress [106, 107].
Some studies examined polymorphism in the gene encoding cholesteryl ester transfer pro‐
tein (CETP), which is involved in the metabolism of high-density lipoprotein (HDL). Pravas‐
tatin-treated patients with either the B1/B1 or B1/B2 genotype (B1 presence and B2 absence
of polymorphism) had significantly less atherosclerotic progression than patients receiving a
placebo. Placebo-treated patients with the B2/B2 genotype had the least progression. How‐
ever, pravastatin-treated patients with the B2/B2 genotype (16% of the study population) de‐
rived no benefit from pravastatin [108, 109].
The substitution (-455G/A) of the fibrinogen gene was found to be associated with an in‐
creased  risk  of  myocardial  infarction  and  stroke.  During  follow-up,  placebo-treated  pa‐
tients  homozygous  for  the  -455A  genotype  had  the  greatest  disease  progression;
although,  no  association  was  found  with  benefit  in  disease  progression  in  patients  on
pravastatin therapy [110].
A five year study of pravastatin therapy in patients with a history of myocardial infarction
and hypercholesterolemia showed that the largest benefit of pravastatin treatment in reduc‐
ing these events occurred in patients with the platelet GP IIIa PlA1/A2 genotype who also
carried at least one D allele of the ACE gene [111, 112].
An effect of polymorphism in the alloprotein gene was found on simvastatin therapy in a
Scandinavian study. Among patients who received the placebo and had at least one apolipo‐
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protein e4 allele, the relative risk of death from all causes was higher than in simastatin pa‐
tients with the same polymorphism [113]. This study demonstrates the potential clinical
value of the alloprotein APOE genotype as a robust marker for low-density lipoprotein
(LDL) responses to statin drugs, which might contribute to the identification of a particular‐
ly drug-resistant subgroup of patients [114].
Genetic variants in CYP3A4, which metabolises simvastatin, atorvastatin and lovastatin,
have been associated with variability in statin efficacy. Both a nonsynonymous polymor‐
phism (M445T) as well the CYP3A4*4 haplotype have been associated with lower LDL cho‐
lesterol levels with atorvastatin. However, in carriers of either a CYP3A4 promoter
polymorphism (A290G) or the CYP3A4*1G haplotype the lipid-lowering effect of statins is
not demonstrated [115-117].
Variation in Hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and low-density lip‐
oprotein receptor (LDLR) genes are associated with the LDL-lowering effect of statins. The
H7 haplotype within HMGCR, defined by the presence of three intronic SNPs, has been as‐
sociated with an 11% to 19% reduction in LDL cholesterol with statin treatment in multiple
independent populations as well as ethnically diverse population-based cohorts [107, 114,
118]. The H7 haplotype has been shown to interact with other genetic variants, including a
second HMGCR haplotype, H2, as well as the LDLR L5 haplotype, defined by six SNPs
within the LDLR 3′ untranslated region. Ethnic variations in LDL cholesterol-lowering with
statin treatment is also demonstrated in African-Americans who carry multiple copies of
these haplotypes versus any haplotype alone [106, 118, 119].
Statin-related myotoxicity, especially rhabdomyolysis, is the subject of medical concerns as
it requires changes in medications and treatment discontinuation. It was found that variants
in CYP3A5 and solute carrier organic anion transporter family (SLCO1B1) gene can be po‐
tential predictors of myotoxicity [120-123].
Increased risk of coronary artery disease, coronary heart disease and myocardial infarction
are associated in some studies with a missense SNP, Trp719Arg, in the KIF6 gene (kinesin
family member 6). Statin treatment significantly reduce coronary events in carriers of
Trp719Arg, and SNPs in high linkage disequilibrium with it, whereas no benefit of statin
treatment is reported in noncarriers [124].
The differences in drug-drug interaction profiles among available statins offer the possibility
of reducing the risk of myotoxicity among high-risk patients. The risk of developing the
rhabdomyolysis condition with statin therapy increases at higher therapeutic doses. This ef‐
fect is increased by combination with certain other medications due to drug-drug interac‐
tions. Co-administration of drugs that inhibit the cytochrome P450 (CYP) enzymes
responsible for metabolizing statins, or that interact with the organic anion-transporting pol‐
ypeptides (OATPs) responsible for statin uptake into hepatocytes, substantially increases the
risk of developing myotoxicity. Pitavastatin, a novel statin approved for the treatment of hy‐
percholesterolemia and combined (mixed) dyslipidemia, is not catabolized by CYP3A4, un‐
like other lipophilic statins, and may be less dependent on the OATP1B1 transporter for its
uptake into hepatocytes before clearance [125].
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6. Antiarrhythmic
Many antiarrhythmic agents have antagonistic  effects  on sodium ion and potassium ion
channels  in  the  heart.  A  risk  of  proarrhythmic  effects  of  antiarrhythmic  drugs  and  its
mechanism is  associated with genetic  variations.  Some evidence indicates  that  polymor‐
phisms in genes encoding components of cardiac ion channels have been associated with
congenital arrhythmia syndromes, such as long-QT and idiopathic ventricular fibrillation
syndromes [126].
The fact that the risk of drug-induced arrhythmia usually increases with increasing drug
concentrations also indicates the involvement of liver enzyme polymorphisms. The CYP2D6
gene regulates cytochrome P450 metabolic pathways and some evidence shows an associa‐
tion between poor metaboliser phenotype and antiarrhythmic drug toxicity {127}.
A number of polymorphisms in the N-acetyltransferace 2 gene contribute to different acety‐
lator phenotypes. Rapid acetylators have increased conversion of procainamide by N-acetyl‐
transferase 2 to N-acetylprocainamide (NAPA) consequently leading to the QT-interval
prolongation, and life-threatening ventricular arrhythmias. Slow acetylators will attain an
increased concentration of procainamide levels with normal procainamide dosages, which
can lead to a procainamide- induced lupus-like syndrome [128].
Sotalol, dofetilide and quinidine increase the chances of QT interval prolongation, polymor‐
phic ventricular tachycardia and torsades de pointes. Several genes encoding ion channels
or function-modifying subunits were associated with these syndromes [129],[130-132].
One study suggested that a NOS1AP variant in the gene encoding an accessory protein for
neuronal nitric oxide synthase, was associated with total and cardiovascular mortality dur‐
ing treatment with dihydropyridine calcium channel blockers. Variants in NOS1AP also
have been reported to modulate the risk of arrhythmias, at equivalent QT interval durations,
in patients with the congenital long QT syndrome and to modulate risk for sudden death in
the general population [133-135].
7. Antiplatelet agents
7.1. Aspirin
Pharmacogenetic studies of aspirin response to date have found associations with a few
genes. It was reported that PLA2 (Leu59Pro) carriers, the variant in platelet glycoprotein
IIIa, have impaired aspirin responses. After seven days of aspirin therapy in healthy volun‐
teers, plasma prothrombin fragment concentrations in bleeding-time wounds were reduced
in 23 of 25 PLA1 homozygotes, compared with 9 of 15 PLA2 carriers [136]. A meta-analysis
[137] of 50 polymorphisms in 11 genes reported in 31 studies with a combined sample size
of 2834 subjects suggested that the common PLA1/2 polymorphism does confer aspirin re‐
sistance (odds ratio in healthy subjects=2.36; P=0.009); however, when combining both
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healthy subjects and those with cardiovascular disease, the odds ratio was 1.14 (P=0.40). The
PLA2 allele occurs with a frequency of approximately 15% in humans and has been associat‐
ed with increased platelet activation and aggregation in vitro [138].
Associations between the PLA polymorphisms and subacute thrombosis after coronary in‐
tervention have been described in some reports [139-141] and it was shown that an in‐
creased risk of subacute thrombosis is associated with the PLA2 allele. In one study, the risk
of subacute thrombosis after coronary angioplasty and stent placement was five times great‐
er in coronary artery disease patients with the PLA2 polymorphism than in patients homo‐
zygous for the PLA1 allele, despite similar antiplatelet therapy and similar clinical,
angiographic and procedural characteristics [139].
7.2. Clopidogrel
The obvious candidates for pharmacogenetic analysis are genes involved in clopidogrel me‐
tabolism. Clopidogrel is a prodrug and its active form, thiol, is formed during the biotrans‐
formation in the liver. CYP2C19, CYP3A4/5, CYP1A2, and CYP2B6 are involved in this
process [142].
P2Y12 belongs to the G protein-coupled purinergic receptor for adenosine diphosphate
(ADP). The P2Y12 protein is found mainly, but not exclusively, on the surface of blood pla‐
telets, and is an important regulator in blood clotting. The active clopidogrel metabolite irre‐
versibly binds to platelet ADP P2Y12 receptors. ADP P2Y12 receptors and loss-of-function
CYP2C19*2 was identified as the single major genetic determinant of biochemical response
to clopidogrel, accounting for approximately 12% of the variation in ADP-stimulated plate‐
let aggregation during drug treatment [143]. CYP2C19*2 carriers treated with clopidogrel
have an increased risk for major adverse cardiovascular events compared to noncarriers and
increased risks of stent thrombosis [144].
Loss-of-function CYP2C19*2 allele has been reproducibly shown to be associated with a de‐
creased conversion of clopidogrel into its active metabolite, reduced antiplatelet effect and
increased risk for cardiovascular events in patients using clopidogrel [4, 145].
The frequency of CYP2C19*2 polymorphism varies in different populations: in Caucasian,
African American, and Mexicans it presence is 18% to 33% (2%–3% homozygotes) and the
allele frequency is higher in Asians. The loss-of-function *3 variant is also associated with
poorer response and is highly prevalent in Asians [146, 147].
P-glycoprotein, also known as multidrug resistance protein 1 (MDR1) or ATP-binding cas‐
sette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243), is a glyco‐
protein that in humans is encoded by the ABCB1 gene. ABC transporters are
transmembrane proteins that utilize the energy of adenosine triphosphate hydrolysis to car‐
ry out certain biological processes including translocation of various substrates across mem‐
branes and non-transport-related processes such as translation of RNA and DNA repair.
Contradicting results have been reported for variants in ABCB1 and Gln192Arg allele in par‐
aoxonase 1, which have been implicated in clopidogrel responsiveness. These associations
need further confirmation [148-150].
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8. Conclusion
Adverse drug reactions (ADRs) have been reported to be the cause for drug withdrawal af‐
ter marketing, hospital admissions, death in hospitalised patients and to be the fourth lead‐
ing cause of death in developed countries. The costs associated with ADRs may radically
escalate the cost for healthcare.
There is an increasing use of multiple medications to treat patients with chronic illnesses.
Drug-drug interactions are common and growing in frequency due to increasing numbers of
medications available and the number of patients on multiple medications. The knowledge
of the pharmacodynamics and pharmacokinetics of the drugs helps to avoid unintended
and problematic drug interactions. Several web sites, books, and cards are available for the
clinician. The web sites are updated on a regular basis and are useful tools for prescribers.
The necessity to understand drug combination pharmacokinetics and pharmacodinamics
in drug interactions is illustrated by the following example: a patient who is taking a drug
equally cleared by CYP2D6 and CYP3A. That patient may not be at  substantial  risk for
toxicity when treated with either a CYP2D6 or CYP3A inhibitor alone, but may be if treat‐
ed  with  both  inhibitors  at  the  same  time  [151].  Pharmacodynamic  or  pharmacokinetic
drug interaction is a complex process and includes understanding of individual variations
in drug metabolism.
Pharmacogenetics has a potential role in reducing ADRs at the pre-marketing and post-mar‐
keting stages of drug development and in clinical care. A priori identification of individuals
at risk of developing ADRs for a given drug will help develop strategies to reduce the risk
for ADRs in these patients. It can also be used to identify individuals at risk of developing
serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs
that are traditionally considered unavoidable to avoidable ADRs.
Although pharmacogenetics is a highly complex and ever-evolving science, it has amassed
knowledge that can readily be used to provide efficient care to patients. It has been shown
that gene variants that play a role in drug metabolism pathways can alter a patient's re‐
sponse or increase toxicity at normal dosage range, especially in combinational drug treat‐
ments. Pharmacogenetics seeks to understand the nature of variable drug responses. Several
pharmacogenetics tests are already available for cardiovascular medications in biomedical
laboratories (Table 1).
Pharmacogenetic findings may help to explain ethnic differences in drug response. The ac‐
cumulated facts of ethnic differences in cardiovascular drug responses and the fact that
many genetic polymorphisms differ in frequency on the basis of ethnicity (example in the
Western Sydney population, Fig. 1) will undoubtedly support future development of phar‐
macogenetics in patient care and in drug interaction interpretation.
It  is  possible  that  use  of  genetic  and other  patient-specific  information,  including  envi‐
ronmental  factors  will  help  guide  drug  therapy  decisions  for  certain  drugs  and  drug
combinations.
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Figure 1. Example of diversity in prevalence of clinically relevant polymorphisms. (*Western Sydney Population com‐
bined data. WSLHD population is a mix of Caucasians, Asians and Africans.)
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Appendix
Glossary of some Pharmacogenetic Terms
• Allele: An alternative form of a gene at a given locus.
• Genetic polymorphism: Minor allele frequency of ≥1% in the population.
• Genome: The complete DNA sequence of an organism. Sum total of the genetic material
included in every cell of the human body, apart from the red blood cells.
• Genomewide association study (GWAS): A genetic association study in which the densi‐
ty of genetic markers and the extent of linkage disequilibrium are sufficient to capture a
large proportion of the common variation in the human genome in the population under
study, and the number of specimens genotyped provides sufficient power to detect var‐
iants of modest effect.
• Genotype: The alleles at a specific locus an individual carries. The genetic constitution of
an individual, i.e. the specific allelic makeup of an individual.
• Haplotype: A group of alleles from two or more loci on a chromosome; inherited as a
unit.
• Heterozygote: A person who has two copies of an allele that are different.
• Homozygote: A person who has two copies of an allele that are the same.
• Pharmacogenetics: A study of genetic causes of individual variations in drug response. In
this review, the term "pharmacogenetics" is interchangeable with "pharmacogenomics."
• Pharmacogenomics: Genomewide analysis of the genetic determinants of drug efficacy
and toxicity. Pharmacogenetics focuses on a single gene while pharmacogenomics studies
multiple genes.
• Phenotype: Observable expression of a particular gene or genes.
• Single nucleotide polymorphism (SNP): is a DNA sequence variation occurring when a
single nucleotide in the genome differs between members of a biological species or paired
chromosomes in an individual.
Useful Internet Resources and databases:
• OMIM (Online Mendelian Inheritance in Man), National Centre for Biotechnology Infor‐
mation (NCBI): www.ncbi.nlm.nih.gov/sites/entrez?db=omim
• PharmGKB (The Pharmacogenetics and Pharmacogenomics Knowledge Base):
www.pharmgkb.org/#public
• NCBI, Individual SNP information, such as genetic location, nucleotide and amino acid
changes, and allele frequencies in diverse populations, can be obtained from dbSNP:
www.ncbi.nlm.nih.gov/sites/entrez?db=snp
Drug Interactions, Pharmacogenomics and Cardiovascular Complication
http://dx.doi.org/10.5772/48423
91
• Databases: ensembl (www.ensembl.org/index.html) and HapMap (www.hapmap.org/cgi-
perl/gbrowse/hapmap_B35)
• FDA: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics
• FDA: Table of Pharmacogenomic Biomarkers in Drug Labels: http://www.fda.gov/Drugs/
ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
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